Research progress of chimeric antigen receptor-transduced-T cells in B-cell malignancies
10.3760/cma.j.issn.1009-9921.2014.12.016
- VernacularTitle:嵌合抗原受体T细胞在B细胞性血液肿瘤中的研究进展
- Author:
Lili XU
;
Yang WANG
- Publication Type:Journal Article
- Keywords:
Chimeric antigen receptor;
Immunotherapy;
Gene therapy
- From:
Journal of Leukemia & Lymphoma
2014;23(12):757-760
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor-transduced-T (CAR-T) cells shows strong cytotoxicity to the tumor with specific antigen by CTL effects and cytokines releasing without MHC-restriction.As multiple clinical trials from cancer centers around the West countries reported recent years,anti-CD19-CAR T cells can not only induce complete remission of B-cell malignancies resistant,but also eliminate the minimal residual disease (MRD) at the molecular level.It is believed that the obstacles from bench to clinic will be cleared and CAR will become one of the main cancer therapies with breakthroughs in comprehensive treatment of tumors.
